D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 122 Citations 66,183 693 World Ranking 1446 National Ranking 44

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Pieter Sonneveld focuses on Internal medicine, Multiple myeloma, Surgery, Oncology and Bortezomib. In his study, which falls under the umbrella issue of Internal medicine, Cytarabine and Carfilzomib is strongly linked to Gastroenterology. The study incorporates disciplines such as Dexamethasone and Pathology in addition to Multiple myeloma.

His Oncology study incorporates themes from Retrospective cohort study, Regimen, Immunology and Daratumumab. He interconnects Cancer research and Multiple drug resistance in the investigation of issues within Immunology. Pieter Sonneveld works mostly in the field of Bortezomib, limiting it down to topics relating to Peripheral neuropathy and, in certain cases, Dose Modification, as a part of the same area of interest.

His most cited work include:

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)
  • International uniform response criteria for multiple myeloma (2049 citations)
  • Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma (1952 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Multiple myeloma, Oncology, Bortezomib and Surgery. His Internal medicine study frequently links to other fields, such as Gastroenterology. His Multiple myeloma study combines topics from a wide range of disciplines, such as Newly diagnosed and Clinical trial.

His Oncology study integrates concerns from other disciplines, such as Pomalidomide, Hazard ratio, Randomized controlled trial and Daratumumab. His studies deal with areas such as Proteasome inhibitor, Hematology and Pharmacology as well as Bortezomib. His research is interdisciplinary, bridging the disciplines of Adverse effect and Surgery.

He most often published in these fields:

  • Internal medicine (64.40%)
  • Multiple myeloma (58.87%)
  • Oncology (35.94%)

What were the highlights of his more recent work (between 2018-2021)?

  • Multiple myeloma (58.87%)
  • Internal medicine (64.40%)
  • Oncology (35.94%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Bortezomib. Pieter Sonneveld has included themes like Cancer research and Clinical trial in his Multiple myeloma study. His work on Daratumumab, Newly diagnosed, Lenalidomide and Transplantation as part of his general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science.

His work carried out in the field of Oncology brings together such families of science as Carfilzomib, Randomized controlled trial, Indirect comparison, Maintenance therapy and Monoclonal antibody. His Dexamethasone study combines topics in areas such as Refractory, Gastroenterology, Stem cell, Subgroup analysis and Bortezomib/thalidomide. His work in Bortezomib addresses subjects such as Melphalan, which are connected to disciplines such as Prednisone.

Between 2018 and 2021, his most popular works were:

  • Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (261 citations)
  • A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (125 citations)
  • Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial (91 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Bortezomib. His study in the field of Daratumumab is also linked to topics like In patient. In most of his Internal medicine studies, his work intersects topics such as Gastroenterology.

His Oncology research includes elements of Ixazomib, Survival rate, Randomized controlled trial, Minimal residual disease and Monoclonal antibody. His research integrates issues of Relapsed refractory, Refractory and Cancer research in his study of Dexamethasone. He has researched Bortezomib in several fields, including Progression-free survival, First relapse and Melphalan.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International uniform response criteria for multiple myeloma

B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Leukemia (2006)

2975 Citations

International staging system for multiple myeloma.

Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley.
Journal of Clinical Oncology (2005)

2970 Citations

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)

2881 Citations

Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

Philip T;Guglielmi C;Hagenbeek A;Somers R.
The New England Journal of Medicine (1995)

2846 Citations

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)

2665 Citations

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)

1144 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka.
The New England Journal of Medicine (2016)

1105 Citations

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari.
Journal of Clinical Oncology (2012)

923 Citations

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Leukemia (2009)

866 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Pieter Sonneveld

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 367

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 344

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 333

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 319

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 281

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 262

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 260

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 242

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 223

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 211

Nikhil C. Munshi

Nikhil C. Munshi

Harvard University

Publications: 208

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 206

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 194

Sagar Lonial

Sagar Lonial

Emory University

Publications: 191

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 190

Martha Q. Lacy

Martha Q. Lacy

Mayo Clinic

Publications: 190

Trending Scientists

Sung Kyu Lim

Sung Kyu Lim

Georgia Institute of Technology

Jean-François Le Gall

Jean-François Le Gall

University of Paris-Sud

M. Y. Hussaini

M. Y. Hussaini

Florida State University

Yin Lu Young

Yin Lu Young

University of Michigan–Ann Arbor

Osvaldo A. Rosso

Osvaldo A. Rosso

National Scientific and Technical Research Council

Kwok-Leung Tsui

Kwok-Leung Tsui

Virginia Tech

Thomas R. Rizzo

Thomas R. Rizzo

École Polytechnique Fédérale de Lausanne

Michelle M. Scherer

Michelle M. Scherer

University of Iowa

John L. Cleveland

John L. Cleveland

Scripps Research Institute

Vassilis I. Zannis

Vassilis I. Zannis

Boston University

Javier Paz-Ares

Javier Paz-Ares

Spanish National Research Council

Iñigo Lasa

Iñigo Lasa

Universidad Publica De Navarra

Duncan Mara

Duncan Mara

University of Leeds

Vivian S. Lee

Vivian S. Lee

University of Pennsylvania

Subrahmanyan Chandrasekhar

Subrahmanyan Chandrasekhar

University of Chicago

Annalisa Bonafede

Annalisa Bonafede

National Institute for Astrophysics

Something went wrong. Please try again later.